乌干达疑似结核患儿粪便mNGS诊断价值评估
该研究对176份乌干达疑似肺结核患儿粪便样本行鸟枪法宏基因组测序(mNGS),以微生物学参考标准评估其检出结核分枝杆菌的准确性,并与粪便Xpert Ultra比较。研究发现mNGS并未提高结核检测灵敏度,但识别出可用于分子检测的新基因靶点,或有助于开发更灵敏的检测方法。
要点
- 粪便mNGS在微生物学参考标准下灵敏度有限,提高判定阈值可提升特异度但灵敏度下降。
- 头对头比较中粪便mNGS灵敏度低于粪便Xpert Ultra。
- mNGS识别出rRNA、毒力蛋白和膜蛋白等现有PCR平台未覆盖的靶点。
核心结论
- 粪便DNA宏基因组测序未提高儿童结核检测灵敏度,但发现了可能支持开发更灵敏分子检测的新靶点。
研究设计与样本
- 研究前瞻性纳入乌干达接受肺结核评估的儿童,对粪便样本行鸟枪法mNGS,以微生物学参考标准(痰Xpert Ultra或培养阳性)和复合参考标准评估准确性,并与粪便Xpert Ultra比较。
主要发现
- 阴性对照组
- 研究分析176份粪便样本,患儿中位年龄3.6岁(IQR 1-6岁)。
- 以微生物学参考标准,阳性判定为≥1、2、5条序列片段时,mNGS灵敏度分别为35.5%(95%CI 19%-55%)、25.7%(12%-45%)、19.4%(13%-25%)。
- 对应特异度分别为92.64%(87%-96%)、97%(93%-99%)、99.3%(96%-100%)。
- 在全部样本中比较,粪便Xpert Ultra灵敏度22.6%,与粪便mNGS相近;头对头比较中粪便mNGS灵敏度低于粪便Xpert Ultra(38.5% vs. 53.8%,差值-15.3%,95%CI 14-68至25-81)。
关键数值与推荐
- mNGS利用了当前PCR平台未覆盖的rRNA、毒力蛋白和膜蛋白靶点。
临床怎么用
- 粪便mNGS不宜作为疑似结核患儿提高灵敏度的常规诊断手段,其识别的新靶点可用于后续分子检测开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stool-based molecular tests provide noninvasive options for pediatric tuberculosis (TB) diagnosis, but have lower sensitivity compared to sputum-based tests. Untargeted metagenomic sequencing (mNGS) on stool could improve sensitivity and identify new gene targets for molecular testing. METHODS: We performed shotgun mNGS on DNA isolated from stool samples of children undergoing assessment for pulmonary TB in Uganda. We defined the performance of mNGS to identify Mycobacterium tuberculosis (Mtb) against a microbiological reference standard (MRS, TB if sputum Xpert Ultra or culture positive) and a composite reference standard (TB if confirmed or unconfirmed TB). We also compared accuracy of mNGS against stool-based Xpert Ultra. Finally, we identified enriched genomic loci among Mtb classified reads. RESULTS: We analyzed 176 stool samples of children with a median age of 3.6 years (IQR, 1-6 years). Against the MRS, the sensitivities of mNGS with positive TB defined as ≥ 1, 2, or 5 sequence fragments were 35.5% (95% CI 19%-55%), 25.7% (12%-45%), and 19.4% (13%-25%) respectively, and specificities 92.64% (87%-96%), 97% (93%-99%), and 99.3% (96%-100%). Stool Xpert Ultra had similar sensitivity (22.6%) to stool mNGS considering all samples tested. In a head-to-head comparison, stool mNGS had lower sensitivity than stool Xpert Ultra (38.5% vs. 53.8%, difference -15.3%, 95% CI 14-68 to 25-81). mNGS utilized rRNA, virulence proteins and membrane proteins not targeted in current PCR-based platforms. CONCLUSIONS: Metagenomic sequencing of stool DNA did not increase sensitivity of TB detection, but identified novel targets for molecular testing that may support development of more sensitive tests.
引用
- Agudelo C, Nsereko M, Ainebyona A, et al. Evaluating metagenomic sequencing as a stool-based diagnostic in children with presumptive TB in Uganda. Clin Infect Dis. 2026. PMID: 42758039. doi:10.1093/cid/ciag573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。